Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib Neoadjuvant Therapy for MIBC (BLASST-3)
NCT04972253Phase 1Withdrawn
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of infigratinib in bladder cancer. Primary endpoint: Proportion of patients receiving at least 1 dose of study treatment followed by completion of radical cystectomy at 3 months. Planned start Dec 2021; status: withdrawn.
02
Drugs
infigratinib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04972253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972253.